In this issue:
Six-month persistence of guselkumab in PsA
Maintenance of remission of ANCA vasculitis with rituximab
Rituximab as maintenance therapy for ANCA-associated vasculitis
Adalimumab concentrations, antidrug antibodies, and disease activity in RA
Serious infections in SLE after rituximab
Infections in RA receiving abatacept and other DMARDs
Effect of socioeconomic deprivation on TNF inhibitor treatment in RA
Treatments for chronic calcium pyrophosphate crystal inflammatory arthritis
Antimalarials + biologics or JAK inhibitors in RA
Real-world outcomes in RA treated with upadacitinib
Please login below to download this issue (PDF)